What Is AOD-9604?
AOD-9604 (Advanced Obesity Drug) is a stabilised peptide fragment derived from the C-terminal region of human growth hormone (hGH), specifically amino acids 176–191. Researchers isolated this fragment after observing that the fat-burning activity of hGH resided in this region, while the growth-promoting and insulin-desensitising effects did not.
Mechanism of Action
AOD-9604 activates beta-3 adrenergic receptors in adipose tissue, stimulating lipolysis — the breakdown of stored triglycerides into free fatty acids. Unlike full hGH, it does not significantly bind IGF-1 receptors, meaning it does not promote tissue growth or impair glucose metabolism at research doses.
Preclinical models have demonstrated:
- Selective reduction of visceral and subcutaneous fat depots
- No measurable effect on blood glucose or insulin sensitivity
- Preservation of lean muscle mass during caloric restriction
Clinical Research
Phase IIb trials conducted in overweight adults found statistically significant reductions in body fat versus placebo over 12 weeks, with a favourable safety profile. The compound was granted GRAS (Generally Recognised As Safe) status by the FDA in 2014 for use as a food additive, underscoring its benign metabolic footprint.
Research Considerations
AOD-9604 is available exclusively for in-vitro and in-vivo research use. Lyophilised peptide should be reconstituted with sterile bacteriostatic water and stored at −20°C prior to use.
Related compounds: Semaglutide, Retatrutide, Tirzepatide.